<ARTICLE> 5 <MULTIPLIER> 1,000 <PERIOD-TYPE> 6-MOS <FISCAL-YEAR-END> DEC-31-1996 <PERIOD-START> JAN-01-1996 <PERIOD-END> JUN-30-1996 <CASH> 73,700 <SECURITIES> 0 <RECEIVABLES> 712,500<F1> <ALLOWANCES> 0 <INVENTORY> 402,400 <CURRENT-ASSETS> 1,704,900<F2> <PP&E> 3,170,700 <DEPRECIATION> 1,398,900 <TOTAL-ASSETS> 6,305,800<F2> <CURRENT-LIABILITIES> 2,301,100 <BONDS> 1,262,800 <PREFERRED-MANDATORY> 0 <PREFERRED> 7,400 <COMMON> 98,700 <OTHER-SE> 1,159,900 <TOTAL-LIABILITY-AND-EQUITY> 6,305,800 <SALES> 1,834,900<F3> <TOTAL-REVENUES> 1,852,800 <CGS> 1,103,800 <TOTAL-COSTS> 1,103,800 <OTHER-EXPENSES> 0 <LOSS-PROVISION> 0 <INTEREST-EXPENSE> 36,700 <INCOME-PRETAX> 429,600<F4> <INCOME-TAX> 154,900 <INCOME-CONTINUING> 274,700<F4> <DISCONTINUED> 122,800<F5> <EXTRAORDINARY> 0 <CHANGES> 0 <NET-INCOME> 397,500 <EPS-PRIMARY> 4.09 <EPS-DILUTED> 4.00 <FN> <F1>Amount shown is net of allowances. <F2>Included within current assets and total assets are net assets of discontinued operations of $296,900 and $1,868,500, respectively. <F3>Excludes sales reported by the discontinued health care segment of $1,105,200 for the first half of 1996. <F4>Includes (i) a gain of $326,400 ($210,100 after-tax) on the sales of businesses, principally the water treatment and process chemicals business, and (ii) a charge of $53,700 ($32,400 after-tax) relating to restructuring costs. <F5>Includes (i) after-tax income of $43,400 from health care operations and (ii) an after-tax gain of $79,400 on the sale of the transgenic plant business of Grace's Agracetus subsidiary. </FN>